Home

усърден главен готвач отделен borsa molmed Направете го тежък химн разсъмване

I giapponesi di Agc l'anciano un'Opa su Molmed e il titolo corre in borsa
I giapponesi di Agc l'anciano un'Opa su Molmed e il titolo corre in borsa

Molmed, l'Opa giapponese in bilico per golden power - ilGiornale.it
Molmed, l'Opa giapponese in bilico per golden power - ilGiornale.it

European Population Genetic Substructure: Further Definition of Ancestry  Informative Markers for Distinguishing among Diverse European Ethnic Groups  | Molecular Medicine | Full Text
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text

Will MolMed soon have its first Cell therapy on the Market?
Will MolMed soon have its first Cell therapy on the Market?

Voluntary Tender Offer launched by AGC Inc. on all ordinary shares of MolMed:  the Board of Directors approves the Issuer's not
Voluntary Tender Offer launched by AGC Inc. on all ordinary shares of MolMed: the Board of Directors approves the Issuer's not

Small Cap Conference 2013: listed SMEs meet investors at Borsa Italiana
Small Cap Conference 2013: listed SMEs meet investors at Borsa Italiana

European Population Genetic Substructure: Further Definition of Ancestry  Informative Markers for Distinguishing among Diverse European Ethnic Groups  | Molecular Medicine | Full Text
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text

Press release issued by MolMed S.p.A. at the request of AGC Inc. NOT FOR  RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PA
Press release issued by MolMed S.p.A. at the request of AGC Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PA

Press release issued by MolMed S.p.A. upon request of AGC Inc. NOT FOR  RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART
Press release issued by MolMed S.p.A. upon request of AGC Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART

COMUNICATO STAMPA
COMUNICATO STAMPA

L'ok Ue fa volare Molmed (+11%) - MilanoFinanza.it
L'ok Ue fa volare Molmed (+11%) - MilanoFinanza.it

Antioxidants | Free Full-Text | Cellular Aging Characteristics and Their  Association with Age-Related Disorders
Antioxidants | Free Full-Text | Cellular Aging Characteristics and Their Association with Age-Related Disorders

Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor  immunity in pancreatic cancer - ScienceDirect
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer - ScienceDirect

Il 2019 è l'anno della svolta per MolMed - MilanoFinanza.it
Il 2019 è l'anno della svolta per MolMed - MilanoFinanza.it

MolMed now part of AGC Biologics | LinkedIn
MolMed now part of AGC Biologics | LinkedIn

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY  OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER

MolMed - Wikipedia
MolMed - Wikipedia

MolMed now part of AGC Biologics | LinkedIn
MolMed now part of AGC Biologics | LinkedIn

Sergio Signore (@signore_sergio) / Twitter
Sergio Signore (@signore_sergio) / Twitter

MOLMED S.P.A. : MLM Stock Price | IT0001080248 | MarketScreener
MOLMED S.P.A. : MLM Stock Price | IT0001080248 | MarketScreener

Relazione sulla Remunerazione MolMed S.p.A.
Relazione sulla Remunerazione MolMed S.p.A.

MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK  for high-risk leukaemia in the United States
MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK for high-risk leukaemia in the United States

Will MolMed soon have its first Cell therapy on the Market?
Will MolMed soon have its first Cell therapy on the Market?

Aptamer-Based Antibacterial and Antiviral Therapy against Infectious  Diseases | Journal of Medicinal Chemistry
Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases | Journal of Medicinal Chemistry

Will MolMed soon have its first Cell therapy on the Market?
Will MolMed soon have its first Cell therapy on the Market?